The science of health 
Home 
Questo sito in ItalianoSunday 05 September 2010
July 15, 2010 Alfa Wassermann: the consolidated balance sheet as of December 31, 2009
The Consolidated Balance 2009
March 26, 2010 FDA approves Rifaximin in Hepatic Encephalopathy (HE) treatment
February 23, 2010 The FDA Advisory Committee recommends approval of Rifaximin in Hepatic Encephalopathy (HE)
December 14, 2009 Rifaximin in the treatment of Irritable Bowel Syndrome (IBS). The Dark Side of IBS
July 15, 2009 Alfa Wassermann: the consolidated balance sheet as of December 31, 2008
The Consolidated Balance 2008
June 15, 2009 ALFA WASSERMANN, A NEW SCENARIO FOR RIFAXIMIN
November 27, 2008 A PHASE III CLINICAL TRIAL HAS DEMONSTRATED THE EFFICACY OF RIFAXIMIN IN THE PREVENTION OF HEPATIC ENCEPHALOPATHY.
October 6, 2008 ALFA WASSERMANN IN TURKEY, GATEWAY TO THE MIDDLE EAST
June 4, 2008 ITALIAN PHARMACEUTICALS SET TO CONQUER RUSSIA
May 15, 2008 Alfa Wassermann: the consolidated balance sheet as of December 31, 2007
The Consolidated Balance 2007
[1] 2 3 4
